Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration

다국어 초록 (Multilingual Abstract)

Objective: The purpose of the current study was to evaluate survival outcome according to the expression status of CD73 in patients with epithelial ovarian cancer.
Methods: A total of 167 patients with epithelial ovarian cancer were enrolled in the current study. For each patient, a retrospective review of medical records was conducted. Immunohistochemical staining for CD73, CD8, FoxP3, and CD68 was performed using tissue microarray made with paraffin embedded tissue block.
Results: Among the enrolled patients, 29.9% of patients (n=50) showed negative expression for CD73, whereas 70.1% of patients (n=117) showed positive expression for CD73. The CD73 positive group showed better prognosis compared to the CD73 negative group (5-year overall survival of CD73 positive group, 73.0%; that of CD73 negative group, 50.1%; p=0.023). CD73 was more frequently expressed in mucinous adenocarcinoma and clear cell carcinoma compared to serous or endometrioid adenocarcinoma. In addition, CD73 overexpressions were more frequently detected in patients with known good prognostic factors, i.e., low stage, well/moderate differentiation, negative peritoneal cytology, no lymphovascular involvement, and no macroscopic residual tumor after debulking surgery. There was significantly more infiltration of regulatory T cells in the CD73 negative group compared to the CD73 positive group.
Conclusion: Good prognosis in patients with overexpression of CD73 may be due to that overexpression of CD73 was more frequently observed in epithelial ovarian cancer patients with known good prognostic factors. Therefore, this result means that favorable differentiation and stage have more influence on survival outcome than adverse effect of CD73 per se.

다국어 초록 (Multilingual Abstract)

Objective: The purpose of the current study was to evaluate survival outcome according to the expression status of CD73 in patients with epithelial ovarian cancer.
Methods: A total of 167 patients with epithelial ovarian cancer were enrolled in the current study. For each patient, a retrospective review of medical records was conducted. Immunohistochemical staining for CD73, CD8, FoxP3, and CD68 was performed using tissue microarray made with paraffin embedded tissue block.
Results: Among the enrolled patients, 29.9% of patients (n=50) showed negative expression for CD73, whereas 70.1% of patients (n=117) showed positive expression for CD73. The CD73 positive group showed better prognosis compared to the CD73 negative group (5-year overall survival of CD73 positive group, 73.0%; that of CD73 negative group, 50.1%; p=0.023). CD73 was more frequently expressed in mucinous adenocarcinoma and clear cell carcinoma compared to serous or endometrioid adenocarcinoma. In addition, CD73 overexpressions were more frequently detected in patients with known good prognostic factors, i.e., low stage, well/moderate differentiation, negative peritoneal cytology, no lymphovascular involvement, and no macroscopic residual tumor after debulking surgery. There was significantly more infiltration of regulatory T cells in the CD73 negative group compared to the CD73 positive group.
Conclusion: Good prognosis in patients with overexpression of CD73 may be due to that overexpression of CD73 was more frequently observed in epithelial ovarian cancer patients with known good prognostic factors. Therefore, this result means that favorable differentiation and stage have more influence on survival outcome than adverse effect of CD73 per se.

참고문헌 (Reference)

1 Reinartz S, "Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II)" 10 : 1580-1587, 2004

2 Aoki Y, "Use of adoptive transfer of tumorinfiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer" 51 : 1934-1939, 1991

3 Spychala J., "Tumor-promoting functions of adenosine" 87 : 161-173, 2000

4 Curiel TJ, "Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival" 10 : 942-949, 2004

5 Kryczek I, "Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma" 67 : 8900-8905, 2007

6 Woo EY, "Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer" 61 : 4766-4772, 2001

7 Leffers N, "Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer" 58 : 449-459, 2009

8 Gabrilovich DI, "Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells" 2 : 1096-1103, 1996

9 Gulley JL, "Pilot study of vaccination with recombinant CEAMUC- 1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma" 14 : 3060-3069, 2008

10 Colgan SP, "Physiological roles for ecto-5'-nucleotidase (CD73)" 2 : 351-360, 2006

11 Adams SF, "Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer" 115 : 2891-2902, 2009

12 Clarke B, "Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss" 22 : 393-402, 2009

13 Stumpf M, "Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes" 101 : 1513-1521, 2009

14 Sato E, "Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer" 102 : 18538-18543, 2005

15 Hoskin DW, "Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review)" 32 : 527-535, 2008

16 Hodi FS, "Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients" 105 : 3005-3010, 2008

17 Gajewski TF, "Immune suppression in the tumor microenvironment" 29 : 233-240, 2006

18 Resta R, "Ecto-enzyme and signaling functions of lymphocyte CD73" 161 : 95-109, 1998

19 Wang L, "Ecto-5'- nucleotidase promotes invasion, migration and adhesion of human breast cancer cells" 134 : 365-372, 2008

20 Edwards RP, "Comparison of toxicity and survival following intraperitoneal recombinant interleukin- 2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion" 15 : 3399-3407, 1997

21 Jin D, "CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression" 70 : 2245-2255, 2010

22 Vlad AM, "A phase II trial of intraperitoneal interleukin- 2 in patients with platinum-resistant or platinumrefractory ovarian cancer" 59 : 293-301, 2010

23 Rackley RR, "5'-nucleotidase activity in prostatic carcinoma and benign prostatic hyperplasia" 49 : 3702-3707, 1989